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The longitudinal evolution of HIV-1 phenotypes
was studied in a cohort of six vertically infected
children with early onset and rapid progression of
clinical disease. Among 30 viral isolates obtained
from peripheral blood, tropisms for both human
blood-derived cells (macrophages, T-lymphocytes), and for human neural (brain-derived) cells
(microglia, astrocytes) were determined, as was
chemokine co-receptor usage. All children harbored from birth macrophage-tropic isolates
using the CCR5 co-receptor. Two children later
developed T-cell tropic isolates with C X C R 4
and CCR3 usage. While all six patients developed
neurological abnormalities, only three produced
neural cell tropic isolates, which used CCR5. However, early and persistent finding of both astrocyte- and microglia-tropic isolates in one patient
did associate with the most rapid progression to
brain atrophy among the six patients. Viral
phenotypic properties determined in cell culture
did not specifically predict clinical features or
course, and the development of AIDS did not
coincide with, or depend on, the appearance
T-tropic, syncytia-inducing viruses. J. Med.
Virol. 67: 1-8,2002.

KEY WORDS: HIV-1 infections; pediatrics;
neuroglia; astrocytes; macrophages; chemokine receptors

INTRODUCTION
Children with human immunodeficiency virus type 1
(HIV-1) infection may develop a broad spectrum of
clinical disease that is variable in both age at onset
of serious disease and progression [Blanche et al.,
1990, 1994; Newell, 19911. Most pediatric infection is

acquired perinatally and, in infants, HIV-1 disease
progression may be influenced by the timing of virus
transmission to the infant, i.e., in utero or intrapartum.
Rapid disease progression is reported in 10-20% of
infected infants, and is more probable with in utero
transmission [Dickover et al., 1994; Mayaux et al.,
1996; Kuhn et al., 19971. These infants are more likely
to have an accelerated decline in their CD4+ lymphocyte counts, experience early developmental delay,
develop AIDS defining conditions, and die before 4 years
of age [Scott et al., 1989; Blanche et al., 1990; Newell,
1991; Duliege et al., 1992; Tovo et al., 1992; Turner
et al., 19931. Other children have a later onset and
slower progression of disease, with a slower decline in
immune function andlonger survival [Auger et al., 1988;
Scott et al., 1989; Blanche et al., 1990; European
Collaborative Study, 1991; Duliege et al., 1992; Blanche
et al., 1994; Italian Registrar, 19941. In the current era
of highly active antiretroviral therapy and early HIV-1
diagnosis, it is anticipated that fewer infants will
develop encephalopathy and rapid disease progression.
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Vertical transmission of HIV-1 may be associated
with a phenotypically homogeneous population of
viruses at birth [McNearney et al., 1992; Wolinsky
et al., 1992; Mulder-Kampinga et al., 19931. Then
longitudinal changes may occur in HIV-1 viral genotype, i.e., the genetic sequence in certain viral genes, or
in HIV-1 viral phenotype, i.e., the cellular tropisms and
co-receptor usage. However, longitudinal changes in
viral genotype or phenotype have not been definitively
correlated with clinical disease progression in individual patients [Fitzgibbon et al., 19981. The immune
response and possibly other selective pressures may act
on the viral envelope glycoprotein gene region during
infection to drive the evolution of the virus population
toward expanding cell tropisms and increased cytopathicity. Several studies, including our own, have
shown that viral sequences in the envelope glycoprotein
are more homogeneous early in infection, and sequence
diversity increases with disease progression and a fall
in CD4+ T-cell count [Hutto et al., 1996; Nowak and
Bangham, 1996; Salvatori et al., 1997; Markham et al.,
19981. Most viruses isolated from adults and children
close to the time of transmission are macrophage tropic
and non-syncytium-inducing (NSI) [Roos et al., 1992;
Spencer et al., 1994; Balotta et al., 19971, and they use
predominantly chemokine receptor CCR5 as co-receptor [Zhang et al., 19981. In older children and adults,
the emergence of T-cell tropic, syncytium-inducing (SI)
virus isolates using chemokine receptor CXCR4 and, in
some cases, CCR3, is associated with rapid disease
progression [Cheng-Mayer et al., 1989;Tersmette et al.,
1989; De Rossi et al., 1993; Balotta et al., 1996; Coombs
et al., 1996; Katzenstein et al., 1996; Koot et al., 1996;
Fitzgibbon et al., 1998; Zhang et al., 19981. During the
first year of life, however, NSI isolates seem to predominate irrespective of clinical course [Spencer et al.,
1994; van't Wout et al., 19941. After progression of
disease occurred, the majority of viral isolates acquired
the ability to use CXCR4 and, in some cases, CCR3,
while losing the ability to use CCR5.
While neurological illness is prominent in rapidly
progressive pediatric HIV-1 infection, there are limited
prospective data on viral tropisms for brain-derived cell
types. Productive HIV-1 infection in the brain occurs in
microglia, which are resident central nervous system
(CNS) cells of monocyte origin [Bagasara et al., 19961.
In adults, HIV-1 isolates exhibit tropism for microglia
that usually correlates with tropism for macrophages
[Strizki et al., 19961 and the use of the CCR5 and CCR3
co-receptors [He et al., 19971. In contrast, HIV-infection
of astrocytes is restrictive or nonproductive, with very
limited virus production and the predominant expression of nonstructural HIV proteins such as nef [Tornatore et al., 1991, 1994a,b; Blumberg et al., 1994; Ranki
et al., 19951. Cellular tropism for astrocytes loosely
correlates with tropism for lymphocytes [McCarthy
et al., 19981, and neurological disease during HIV-1
infection may result from neuronal and astrocyte
apoptosis mediated by HIV-1 strains that interact with
CXCR4 receptors on these neuroepithelial lineage cells

[Ohagen et al., 19991. Restricted or nonproductive
HIV-1 infection of astrocytes occurs in both pediatric
and adult brains, suggesting that astrocytes function as
a reservoir for latent virus in the CNS [Saito et al.,
1994; Tornatore et al., 1994a; Ranki et al., 1995;
Takahashi et al., 19961.
This study assesses the longitudinal evolution of
cellular tropisms manifested by HIV-1 viruses isolated
prospectively from a cohort of vertically infected children with early onset and rapid progression of clinical
disease. The study specifically examines (1)tropisms
for both human blood-derived cells (macrophages, T
lymphocytes), and for human neural (brain-derived)
cells (microglia, astrocytes); and (2) the corresponding
longitudinal evolution of co-receptor usage by the viral
isolates. These prospective data provide insight into the
changes in viral phenotypic characteristics evolving
early in the lifetimes of children with rapid HIV-1
disease progression.

MATERIALS AND METHODS
Description of the Cohort
A total of 35 children with perinatally acquired HIV
infection were followed prospectively from birth. For all
study patients, written informed consent was obtained
from the child's parent or legal guardian. This study
was approved by, and conducted according to the
guidelines of the institutional review board of the
University of Miami School of Medicine, the Medical
Sciences Subcommittee for the Protection of Human
Subjects. Clinical and laboratory data were collected
every 3 months, and blood samples were drawn for HIV
culture and plasma storage starting in the perinatal
period and continuing throughout life. Six children
with rapid disease progression were selected for
this study based on having an adequate number of
isolates to study. Rapid progressors had absolute CD4+
counts of 11,000/mm3 during the first year of life, or
< 500/mm3during the second year of life, or had one or
more of the AIDS defining criteria [Centers for Disease
Control, 19941 during the first 2 years of life.

Viral Assays
HIV-1 viral load was determined in plasma using the
standard Roche Amplicor HIV-1 Monitor Test (Roche
Diagnostics Corporation, Indianapolis, IN). HIV-1 isolates were obtained by culture of the individual's
peripheral blood mononuclear cells (PBMC) according
to standard HIV-1 isolation techniques [AIDS Clinical
Trials Group, 19941. Virus production was monitored
by measuring HIV-1 p24 antigen levels, using a commercial enzyme-linked immunoassay kit (Beckman
Coulter, Hialeah, FL).

Virus Titration and TCID50Calculation
Virus stocks were prepared when p24 antigen
exceeded 10 ng/ml, and the titers were determined by
limiting dilution to obtain the 50% tissue culture
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infectious dose (TCID50) as described in the AIDS
Clinical Trials Group (ACTG) virology manual for HIV
laboratories, though with some modifications [AIDS
Clinical Trials Group, 19941. Briefly, serial fourfold
dilutions of virus stocks, from 1:12 to 49,152, in a final
volume of 150 111, were incubated in triplicates in flatbottomed 96-well tissue culture plates with 50 p1 of
phytohemagglutinin assay (PHA)-stimulated PBMC
containing 200,000 cells, pooled from two uninfected
donors. At day 4, 125 p1 of the culture media were
removed and replaced with 150 p1 of fresh media.
Supernatants were tested for the presence of p24
antigen at day 7. The TCIDBO
were calculated according
to the Spearman-Karber method as described in the
ACTG manual [AIDS Clinical Trials Group, 19941.

with 2 pglml Polybrene (Sigma Chemical Co., St. Louis,
MO) for 1hr at 37'C and then incubated with the virus
isolate at a multiplicity of infection (moil of 500 TCID501
lo5 cells for 2 hr at 37'C. After this adsorption step, the
cells were then washed and cultured in the appropriate
medium. Supernatants were harvested at 0,3,7, and 14
days postinfection from all infections except for astrocytes, in which case supernatants were harvested at 0,
1, 2, 3, 4, and 7 days postinfection. Virus production
was monitored by measuring the p24 antigen levels in
the culture supernatants. Cultures were considered
positive for viral growth if > 100 pglml of p24 was
detected. A "weak positive" score was given if only 50100 pg/ml of p24 was present, and a negative score if
< 50 pglml was detected.

Cell Culture

Evaluation of Co-receptorUsage

Fetal CNS tissue for the preparation of astrocyte
cultures was obtained from the Human Embryology
Laboratory, University of Washington (Seattle, WA).
Procedures for the procurement and use of human fetal
CNS tissue were approved and monitored by the
Medical Sciences Subcommittee for the Protection of
Human Subjects of the University of Miami School of
Medicine. Primary fetal human astrocyte monolayers
were grown to 80% confluency on poly-L-lysine-coated
6-well multicluster tissue culture dishes in B16
medium with 5 ng/ml basic fibroblast growth factor
(bFGF) [McCarthy et al., 19951. Primary human
microglia were isolated from adult spinal cord and
plated on uncoated 6-well tissue culture dishes in RPMI
medium containing 5% fetal bovine serum (FBS)
[Whittemore et al., 19931. The T-cell lines, MT-2,
C8166, and CEM x 174-GFP were cultured in RPMI
medium- 10% FBS. Cell line HOS-CD4-CCR3 is from
the NIH AIDS Research Reference and Reagent
Program; it is propagated in DMEM medium containing 10% FBS, and 0.5-1.0 yglml puromycin. GhostCCR5 cells were propagated in DMEM with 10 pg/ml of
hygromycin, 500 yglml of G418, and 1 pg/ml of
puromycin. CEM x 174-GFP and Ghost-CD4-CCR5
cells were supplied by Dr. Weidong Xu (Dana Farber
Cancer Center, Boston, MA). Primary human monocytes were obtained from gradient-purified PBMC by
the plastic adherent technique [Cheng-Mayer et al.,
19891. Adherent cells were cultured for 7-10 days in
RPMI medium containing 10% FBS and 10 ng of
granulocyte-macrophage colony-stimulating factor
(GIBCO-BRL, Gaithersburg, MD) per ml to allow differentiation into macrophages.

Determination of co-receptor usage was carried out
using different cell lines expressing different coreceptors, CXCR4 (CEM x 174-GFP cells), CCR5
(Ghost-CCR5 cells) and CCR3 (HOS-CD4-CCR3
cells) [Cecilia et al., 1998; Morner et al., 19991. To test
for co-receptor usage, all three cell lines were seeded at
a density of 1x lo6 cellslml into each well of a 24-well
plate, infected with 5 ng p24 of HIV-1 per ml of cells,
and on day 2-3 postinfection, the infected CEM x 174GFP and Ghost-CCR5 cells were observed under the
microscope for marker green fluorescent protein (GFP)
expression. A well containing three times or more green
fluorescent cells than the negative control was considered positive. Negative control cells without HIV-1
infection generally produced only one to two GFP
expressing cells per well. HIV-1 strains SF2 or NL4-3
was used as positive control for viruses that use CXCR4
as co-receptor, and HIV-1 strain SF128A was used as
control for viruses that use CCR5 as co-receptor.
Infection by the positive control virus usually gave at
least 7 times more GFP-expressing cells than background control. For infection of HOS-CD4-CCR3, p24
virus production was monitored by measuring HIV-1
p24 antigen levels in the culture supernatants at 3 days
postinfection. Cultures were considered positive for
viral growth if > 100 pglml of p24 was detected.

Determination of Cellular Tropism
Each isolate was tested for its ability to infect
primary human astrocytes (astrocyte tropism), primary
human microglia (microglia tropism), the immortalized
T-cell line MT-2 (T-cell tropism), and primary human
macrophages (macrophage tropism). Virus isolates that
were "T-tropic" were further monitored for syncytia
induction (SI) in cell culture. Cells were first treated

RESULTS
Thirty peripheral blood isolates of HIV-1 were studied. These were obtained from six vertically infected
pediatric patients, all of whom progressed rapidly to
HIV-1 disease. All children were born between June
1990 and July 1995. There were two females and four
males in the cohort; all were of black African American
or Caribbean descent. Three of these patients (patients
422, 275, and 601) were presumed to be infected in
utero, as virus was detected by culture or viral RNA
assay in blood samples obtained within 2 days of birth.
The remaining three patients (patients 202, 290, and
217) were apparently infected intrapartum. The
patients were assessed for longitudinal progression of
clinical disease, occurrence of neurological abnormal-
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TABLE I. Longitudinal Summary of Patient Disease Progression, Neurological Abnormalities, and Cellular Tropism
of Isolates
Patient
202

290
601
422

275
217

Age

m$"

M T - ~ ~ astC

2 wk
2 mo
6 mo
12 mo
20 mo
24 mo
26 mo
2 wk
2 mo
6 mo
Birth
2 mo
12 mo
Birth
2 mo
6 mo
11 mo
2 wk
2 mo
12 mo
2 wk
2 mo
6 mo
12 mo
24 mo
38 mo
45 mo
49 mo

Co-receptor usage

CDC
classe

Neurological
abnormalitiesf

CCRS
CCR5
CCRS
CCR5

CCR~'
CCRS
CCR5
CCRS

CCRS
CCR5
CCRS
CCR5
CCRS
CCR5

"Primary macrophage tropism.
b ~ - c e ltropism
l
as defined by growth on the T-cell line MT-2, virus that -grew in MT-2 cells were also SI
'Primary istrocyte tropism: d ~ r i m a r microglia
y
tropism.
"CDC Clinical Category N, no signstsymptoms; A, mild signs/symptoms; B, moderate signs/symptoms; C, severe signs/symptoms.
f~eurological
abnormalities: -, no abnormalities found; +, developmental delay and/or cognitive abnormalities; ++, CNS atrophy andtor brain
calcification; ND, not determined.

ities, CD4+ lymphocyte count, viral load, and the
cellular tropisms of their viral isolates. Table I and
Figure 1 (arranged arbitrarily by patient number)
summarize the data from all HIV-1 isolates. All
children developed a CDC Category C AIDS defining
illness [Centers for Disease Control, 19941 during the
first 2 years of life. Five of the children died by 30
months of age, and one child (patient 217) still survives.
Neurological abnormalities ranging from developmental delay and/or cognitive dysfunction to CNS atrophy
and/or brain calcification were found a s early as 2
months of age in one child, and in all children by 20
months of age. Therefore, these patients represent a
cohort of vertically HIV-1 infected pediatric patients
whose clinical disease progressed rapidly and included
neurological abnormalities within the first two years of
life. Of the five patients that died, four had declining
CD4 counts during the course of their illness (Fig. 1).
The surviving child (patient 217) is severely immunosuppressed, as evidenced by very low CD4 values.
HIV-1 viral load (viral RNA copies/ml) values are available for five of the six children and show progressive
increase in viral load in three. Four of the children
(patients 422, 601, 202, and 217) received zidovudine
monotherapy within the first 4 months of life because of

early diagnosis of HIV-1 infection and evidence of
clinical disease.
The longitudinal collection of HIV-1 isolates from
each patient was assessed for cellular tropism, which
was defined by the ability of a given isolate to grow in
primary human macrophages, a n immortalized human
T-lymphocyte cell line (MT-2), primary human astrocytes, and primary human microglia. Between birth
and 12 months of age, all six of the children harbored
viruses that were macrophage tropic. In the two children who later developed T-tropic viral isolates
(patients 202 and 217), progression to severe disease
or development of neurological abnormalities did not
predict or depend upon the appearance of the T-tropic
phenotype. Within the first year of life, patient 202
displayed weak gross motor skills and only later, a t 20
months of age, produced viral isolates that had gained
T-cell tropism in addition to macrophage tropism
(Table I, Fig. 1A). This expanded cellular tropism
coincided with the progression to Category C illness
as well a s developmental delay. By 38 months of age,
this patient had delayed fine motor skills and both
expressive and receptive language deficits. In contrast
to patient 202, patient 217 did not develop dual tropic
viruses (able to infect both macrophages and MT-2
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Fig. 1. Individual longitudinal profiles of clinical disease stage,
cellular tropisms, CD4+ lymphocyte counts (cells/mm3),and human
immunodeficiency virus type 1 (HIV-1) viral load (RNA copieslml) in
six vertically infected children with rapid clinical disease progression.
Clinical disease stage according to Centers of Disease Control (CDC)
classification is indicated along the x-axis: open bar, CDC class N;
horizontally striped bar, CDC class A; horizontally cross-hatched bar,

CDC class B; vertically cross-hatched bar, CDC class C; vertical arrow,
death. The appearance of viral isolates with specific cellular tropisms
are indicated along the x-axis of each profile: mQ, macrophage (NSI);
ast, astrocyte; pgl, microglia; MT-2, T-tropic (SI) virus determined by
growth in MT-2 cells as described in the Materials and Methods
section.

cells) until 38 months of age, about 32 months after
progression to severe disease, and 26 months after the
appearance of neurological abnormalities (Table I,
Fig. IF). The remaining four children harbored macrophage tropic viruses throughout life, even after pro-

gression to severe disease and the development of
neurological abnormalities.
Only two of the six children, patients 202 and 422,
ever exhibited viral isolates with cellular tropisms for
both astrocytes and microglia (Table I). In these two

-

-
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children, astrocyte tropism persisted, whereas microglia tropism was transient. A third child, patient 217,
produced astrocyte-tropic isolates within the first 2
weeks of life, but this astrocyte tropism was subsequently lost from later isolates. All microglia-tropic
isolates were found to be macrophage-tropic. There was
no correlation between a change in neural cell tropism
and a change in neurological status. Patient 422 did not
harbor T-tropic isolates at any time and consistently
produced macrophage-tropic strains. Therefore, we did
not observe a correlation between emergence of T-cell
tropism and neural cell tropism (astrocytes or microglia) in this cohort.
Additional experiments were performed to define the
co-receptor usage of the isolates. All isolates produced
by the cohort during the first year of life used the CCR5
co-receptor, which correlated with macrophage tropism
and the NSI phenotype (Table I). When patients 202
and 217 developed T-tropic isolates in addition to their
macrophage-tropic isolates later in the course of
disease, co-receptor usage of their respective isolate
populations expanded to include CXCR4 and CCR3, as
well as CCR5. Interestingly, all viruses that have
evolved to use the CXCR4 co-receptor have also evolved
to use CCR3, and there appeared to be a correlation
between CCR3 and CXCR4 co-receptor usage, at least
in the children that we have tested. In contrast,
patients 202, 422, and 217 produced isolates during
the first year of life that were microglia- andlor astrocyte-tropic but used only the CCR5 co-receptor. Patient
202 at 2 months, and patient 422 at birth, 2 months,
and 6 months, had isolate populations with both
astrocyte and microglia tropisms. Thus, diverse neural
cell tropisms were seen in viral isolate populations
using only CCR5.

DISCUSSION
In this study of six vertically HIV-1-infected pediatric
patients with rapid disease progression, viral phenotype properties did not specifically predict clinical
features or course. Macrophage-tropic viral isolates
and CCR5 chemokine co-receptor usage predominated
and T-tropic (SI) isolates, when they occurred, arose
later in the clinical course. There was no correlation
between the timing of HIV-1 infection, i.e., in utero
versus peripartum, and rapid clinical progression,
although, consistent with the Women and Infants
Transmission Study [Shearer et al., 19971, all patients
had high viral load (> 500,000 RNA copies/ml) during
the first 2 months of life. Clinical neurological manifestations of HIV-1, i.e., encephalopathy and developmental delay, did not depend on the emergence of virus
strains in the peripheral circulation that were infectious for microglia and/or astrocytes in vitro. Macrophage tropism was not equivalent to, nor did it predict,
microglia tropism, although in this cohort, all microgliatropic isolates were also macrophage-tropic. Astrocytetropic isolates obtained from three of the six patients
(patients 202, 422, and 217) were also macrophage-

tropic, and the astrocyte-tropic isolates detected earlier
in the disease course used the CCR5 co-receptor only
(Table I). Furthermore, rapid disease progression and
death occurred in most cases without the emergence of
T-tropic (SI) strains at all, and the development of
AIDS did not coincide with or depend on the appearance of quasi-species able to infect T-cell lines. When SI
strains arose (patients 202 and 217), there was a
simultaneous emergence of viruses that acquired dual
CXCR4 and CCR3 usage in addition to CCR5. It is not
clear whether this is due to a mixture of strains of
viruses that each use a different co-receptor, or to a
single virus that can use CXCR4 and CCR3 in addition
to CCR5. Further cloning of the viruses will be needed
to resolve this issue.
These data are consistent with two prior longitudinal
studies in vertically HIV-1-infected children [Hutto
et al., 1996; Fitzgibbon et al., 19981, and they suggest
that progression of HIV-1 illness in very young children
frequently does not associate with SI virus phenotype.
In a study of 48 children, Fitzgibbon et al. [I9981
observed that rapid progressors in that cohort were no
more likely to produce SI than NSI viruses, and some
rapid progressors died without manifesting SI strains.
Hutto et al. [I9961 studied viral genetic diversity and
cellular tropisms in perinatally infected twins with
discordant disease courses, and found that the rapid
progressor twin did not produce SI or T-tropic isolates
from peripheral blood.
A potential pitfall in the interpretation of our as well
as similar studies is the use of viral isolates derived
longitudinally from peripheral blood. These blood isolates are a mixed population of quasi-species, and could
be expected to exhibit multiple viral phenotypes during
the longitudinal course of HIV-1 infection in the
individual patient. Given the neuroanatomical sequestration of the CNS, these peripheral blood-derived
isolates may not reflect the population of HIV-1 quasispecies resident within the CNS at the time of isolation.
Sequestration of the virus in the CNS-resident microglia cells enables local evolution of CNS-specific quasispecies, which may be independent and divergent
from peripheral quasi-species [Gonzalez-Scarano and
Baltuch, 19991. However, perivascular microglia at
the blood-brain barrier may be exposed to peripheral
HIV-1 quasi-species by circulating lymphoid cells
[Gonzalez-Scarano and Baltuch, 19991. Thus, although
the peripheral HIV-1 isolates may not reflect the CNS
quasi-species at the time of isolation, these peripheral
isolates could reflect the circulating subpopulations of
HIV-1 that are capable of infecting the blood-brain
barrier and entering the CNS as early as birth and
throughout the course of disease. Therefore, peripherally derived isolates are potentially relevant to the
emergence and progression of clinical neurological
disease. In our cohort of six children, the one child
with isolate populations that were both astrocyte-tropic
and microglia-tropic at birth (patient 422) did have the
most rapid onset of more severe neurological abnormalities (CNS atrophy by 6 months of age).

Viral Phenotypes in HIV-Infected Children
In this cohort of six pediatric patients with rapid
progression of HIV-1-related disease, there was no
definitive association between clinical neurological
complications and viral phenotype (cell tropism) or coreceptor usage. All six patients in the cohort developed
neurological abnormalities, but neural cell tropic
viruses were only detected in three patients at any
point in life. However, the early and persistent finding
of both astrocyte and microglia tropic isolates in one
patient (patient 422) did associate with the most rapid
progression to CNS atrophy among the six patients.
Early (patient 217) or early and persistent (patient 202)
astrocyte tropism without microglia tropism did not
associate with more rapid presentation of neurological
complications. In that peripheral blood-derived isolates
may reflect the population of viruses capable of crossing
the blood brain barrier and promoting CNS infection,
the isolates produced by patient 422 during the first
several months of life may have been optimal for
seeding, establishing, and amplifying productive infection of the CNS. Microglia-tropic viruses would be
capable of establishing productive CNS infection in
microglia, while astrocyte-tropic viruses would also
establish restricted or latent CNS infection in astrocytes. The combination of these cellular tropisms could
ultimately amplify the viral burden in the CNS and
accelerate the neurological manifestations of HIV-1
infection in the pediatric patient.
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